(MDRX) Veradigm - Ratings and Ratios

Veradigm Inc. (NASDAQ:MDRX), a healthcare technology company, delivers comprehensive IT solutions to healthcare providers, payers, and biopharma markets in the U.S. and internationally. The company provides a suite of tools for healthcare providers, including Practice Management software, AI-driven Patient Scheduling, Electronic Statements and Payments, and Revenue Cycle Management solutions. Its EHR offerings include ePrescribe with EPCS, Veradigm EHR, and Practice Fusion EHR, alongside a Patient Engagement Platform. The company also offers API connectivity solutions like Veradigm Connect and Veradigm App Expo, as well as a Channel Partner Program and Veradigm ePrescribe Enterprise for network partners.

For health plans and payers, Veradigm provides risk adjustment solutions such as Health Equity Analytics, Risk Adjustment Analytics, and Utilization Analytics. It also offers quality management solutions, data exchange and coding tools like eChart Courier and eChart Coder, and Veradigm Payer Insights. The company serves biopharma with real-world data solutions, including health data sets and registries, real-world evidence platforms, and therapy-focused solutions for cardiovascular, CNS, metabolic, and immunology data. Additionally, it provides Digital Health Media solutions. Formerly known as Allscripts Healthcare Solutions, Inc., the company rebranded as Veradigm Inc. in January 2023. Founded in 1986, it is headquartered in Chicago, Illinois.

3-Month Forecast: Based on , MDRX has shown declining momentum, with its SMA 20 (5.33) and SMA 50 (7.60) below the SMA 200 (9.08), indicating a bearish trend. Average volume of 825,050 shares suggests moderate liquidity. With an ATR of 0.65, price fluctuations are expected to remain controlled. Support levels may form near $4.20, while resistance could cap upside at $6.00. From a perspective, the P/S ratio of 0.36 and P/B of 0.87 suggest undervaluation, potentially attracting value investors. However, the forward P/E of 15.17 indicates cautious sentiment. Overall, MDRX is likely to trade sideways with a slight bearish bias in the near term.